中山有名肛肠医院(中山痔疮手术要几天) (今日更新中)

The US Office of Special Counsel announced Tuesday that White House aide Kellyanne Conway violated the Hatch Act on two occasions by "advocating for and against candidates" in last year's Alabama Senate special election.In a new report, the OSC special counsel, Henry Kerner, pointed to Conway's TV interviews conducted in her "official capacity" in November and December of last year. The agency said Conway "impermissibly mixed official government business with political views about candidates in the Alabama special election."One of the two interviews was on CNN's "New Day," and the second was on Fox News' "Fox & Friends."In a letter to President Donald Trump, Kerner said he is referring her violations for the President's "consideration of appropriate disciplinary action."The White House did not immediately respond to a request for comment.During the "Fox & Friends" interview November 20, Conway was introduced by the show's hosts as a "counselor to President Trump" and spoke from White House grounds. She said about Democratic Senate candidate Doug Jones: "Folks, don't be fooled. He'll be a vote against tax cuts. He's weak on crime, weak on borders. He's strong on raising your taxes. He's terrible for property owners."During the "New Day" interview December 6, Conway -- again speaking from White House grounds and introduced by CNN anchor Chris Cuomo as "counselor to President Trump" -- said among other things that Jones will be a reliable vote "for tax hikes," "against border security," "against national security," "against the Second Amendment" and "against life," according to the OSC report.Conway went on to tell Cuomo that Jones is "out of step for Alabama voters, according to the President," and that Trump "doesn't want a liberal Democrat representing Alabama in the United States Senate."The Office of Special Counsel is unrelated to the investigation by special counsel Robert Mueller.  1940

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The RV industry has seen a significant increase in rentals and sales over the summer. One company, RVshare, reported more than a 1,000% increase in rentals.Now, the trend seems to be moving beyond just a summer vacation alternative. Some are turning to it as a new way to home-school and work during this pandemic.Some families are turning these RVs into their primary or secondary homes."I think it is difficult for families to be cooped up," said Julie Partridge.Partridge was already considering making the switch to RV life before the pandemic, but after five months of social distancing and quarantining in her home, she decided to finally do it.She sold the family home and hit the road to live, home-school her kids and work from an RV."Obviously our camper is much smaller than our house,” said Partridge. “Substantially smaller, but you have this vast open world available to you. You feel less cooped up in this camper than you do in this 3,000 square foot house."She also feels the move to full-time RV life this fall will also give her kids a unique educational opportunity."We really want to see the national parks,” said Partridge. “I want my kids to do the park ranger program. I want to use that as their science and social studies curriculum from the road. So, we are really excited about those parts."The Partridge family is just one of many either committing to or newly considering RV life in the fall, according to a survey done by the RV rental company RVshare."We have, from our survey, seen that over 30% of people are considering homeschooling from the road and over 40% of people are considering working from the road and that is something that is new to the industry," RVshare Jon Gray."You have school not opening on time, you have a lot of employers turning to work from anywhere models for the extended future and those things have made it to where RVs are appealing deep into the fall," said Gray.The pandemic has changed so much in our lives. Many people are looking to get away from the uncertainty and continued concern with it. This seems to be one way for some to do that."It is saving us money, it is teaching them lessons, it has really been kind of refreshing," said Partridge. 2224

The Tulsa Health Department will contact any individual or setting deemed at risk for exposure for all confirmed positive COVID-19 cases among Tulsa County residents. The virus spreads primarily through respiratory droplets among individuals within close personal contact (within 6’) for a prolonged period of time (ten minutes or longer). Anyone with concerns about their risk of exposure can contact the Tulsa Health Department at 918-582-9355.The Tulsa Health Department respects those exercising their right for peaceful assembly. Crowds and large gatherings can be a conduit for the transmission of COVID-19, which is spreading in our community. All residents are encouraged to exercise their right to gather and protest safely, which includes wearing a cloth face covering to protect those around you, use hand sanitizer when soap and water are not readily available, practice social distancing, and avoid touching your face. We want to encourage residents to use their voice, but do so safely.Today, we reported an additional 34 cases and three deaths in our community, bringing the cumulative total to 1,057 and 57 respectively. 1144

The US Centers for Disease Control and Prevention continues to warn against eating any romaine lettuce harvested from the central Coastal growing regions of Northern and Central California amid a multistate outbreak of E. coli illnesses linked to romaine lettuce. The agency also reported Thursday that nine additional people have been reported ill since November 26.Now, 52 people have been infected with E. coli in this outbreak, which was announced in October, according to the CDC.Illnesses have been reported in 15 states: California, Connecticut, Florida, Illinois, Louisiana, Massachusetts, Maryland, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island and Wisconsin.Nineteen people have been hospitalized, including two who developed hemolytic uremic syndrome, a type of kidney failure. No deaths have been reported.Last month, the CDC and the US Food and Drug Administration updated their warning against eating or selling romaine lettuce products harvested in the California counties of Monterey, San Benito, San Luis Obispo, Santa Barbara, Santa Cruz and Ventura. 1110

来源：资阳报